SCHEDULE: Funicular Funds, Cable Car Capital Acquire Nasus Pharma Stake
Beneficial Ownership Filing (Schedule 13G)
Funicular Funds, LP and Cable Car Capital, LP, along with Jacob Ma-Weaver, have collectively acquired a 5.2% stake in Nasus Pharma Ltd.
Summary
- Funicular Funds, LP, Cable Car Capital, LP, and Jacob Ma-Weaver have reported beneficial ownership of 612,913 Ordinary Shares of Nasus Pharma Ltd.
- This holding represents 5.2% of the total outstanding Ordinary Shares.
- The calculation of outstanding shares is based on information provided by Nasus Pharma Ltd. in Post-Effective Amendment No. 1 to Form F-1, filed on March 27, 2026, which stated 11,710,808 shares outstanding.
- Cable Car Capital, LP is the General Partner of Funicular Funds, LP, and Jacob Ma-Weaver is the Managing Member of Cable Car Capital, LP, leading to shared beneficial ownership attribution.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a standard disclosure of beneficial ownership and does not provide operational or financial performance updates.
Positives
- Acquisition of a significant minority stake (5.2%) in Nasus Pharma Ltd. by investment entities and its management.
- Clear reporting of beneficial ownership and percentage of class held.
Risks
- The filing does not contain information on specific risks associated with this investment or Nasus Pharma Ltd.
Future Outlook
The filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or guidance from the company.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to disclose their holdings. This filing indicates a notable investment by Funicular Funds, LP and Cable Car Capital, LP in Nasus Pharma Ltd., suggesting a belief in the company's potential by these investment entities.
Stakeholder Impact
- Shareholders: The acquisition of a 5.2% stake by these entities may signal increased institutional interest or potential for future activism, though no specific intent is stated.
- Management of Nasus Pharma Ltd.: The filing is a disclosure requirement and does not directly impact management operations, but it signifies a significant shareholder group.
Next Steps
- Continued monitoring of Nasus Pharma Ltd.'s performance and any future filings by Funicular Funds, LP, Cable Car Capital, LP, and Jacob Ma-Weaver.
Key Dates
| Date | Description |
|---|---|
| 03/27/2026 | Date of Post-Effective Amendment No. 1 to Form F-1 reporting 11,710,808 shares outstanding. |
| 03/31/2026 | Date of Event Which Requires Filing of this Statement (Schedule 13G filing date). |
| 04/07/2026 | Date of certification and signature for the Schedule 13G filing. |
Keywords
Nasus Pharma Ltd, Schedule 13G, Funicular Funds, LP, Cable Car Capital, LP, Jacob Ma-Weaver, Ordinary Shares, Beneficial Ownership, SEC Filing, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.